Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05858398 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Influence of Body Composition on Chemotherapy Outcomes in Localized Breast Cancer

Study acronym: FATTAX
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 2, 2026 (before its estimated May 2, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: May 2, 2025 to May 2, 2026
    • Start date changed from estimate of May 30, 2023 to Oct 25, 2023
    • Study completion date: May 2, 2026 to May 2, 2027
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine if pharmacokinetics of docetaxel is modified by the body composition (assessed by the BMI but also by CT-scan) in patients treated by docetaxel as adjuvant treatment of a localized breast cancer
Trial Details
NCT Number NCT05858398
Lead Sponsor Centre Henri Becquerel
Collaborators: Erasmus Medical Center, Universitaire Ziekenhuizen KU Leuven
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov